Key Points
- Executive sale: Alnylam EVP Bryan Supran sold 1,758 shares at an average price of $226.88, generating approximately $398,855. The sale covered tax withholding obligations tied to vested equity awards, leaving him with 12,807 shares.
- Stock performance: ALNY opened at $223.94 and remains well below its 52-week high of $495.55, with a market capitalization of approximately $29.97 billion.
- Analyst outlook: Analysts maintain a consensus “Moderate Buy” rating, with an average price target of $366.90, despite several recent target-price reductions.
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Get Free Report) EVP Bryan Supran sold 1,758 shares of the company's stock in a transaction dated Friday, October 2nd. The shares were sold at an average price of $226.88, for a total transaction of $398,855.04. Following the transaction, the executive vice president owned 12,807 shares in the company, valued at approximately $2,905,652.16. This trade represents a 12.07% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Alnylam Pharmaceuticals Stock Performance
Shares of Alnylam Pharmaceuticals stock opened at $223.94 on Wednesday. The company has a 50 day moving average price of $238.92 and a 200 day moving average price of $279.01. The firm has a market capitalization of $29.97 billion, a P/E ratio of 41.62 and a beta of 0.28. The company has a quick ratio of 2.99, a current ratio of 3.05 and a debt-to-equity ratio of 0.75. Alnylam Pharmaceuticals, Inc. has a 52 week low of $197.81 and a 52 week high of $495.55.
Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its earnings results on Thursday, July 30th. The biopharmaceutical company reported $1.84 earnings per share for the quarter, topping the consensus estimate of $1.63 by $0.21. Alnylam Pharmaceuticals had a net margin of 15.26% and a return on equity of 84.93%. The company had revenue of $1.29 billion for the quarter, compared to the consensus estimate of $1.32 billion. During the same quarter in the previous year, the firm earned ($0.51) EPS. Alnylam Pharmaceuticals's revenue was up 66.9% compared to the same quarter last year. Sell-side analysts expect that Alnylam Pharmaceuticals, Inc. will post 6.71 EPS for the current year.
Analyst Ratings Changes
Several research firms recently issued reports on ALNY. Needham & Company LLC cut their target price on Alnylam Pharmaceuticals from $510.00 to $357.00 and set a "buy" rating on the stock in a research report on Thursday, July 30th. HC Wainwright reaffirmed a "buy" rating and set a $455.00 price target on shares of Alnylam Pharmaceuticals in a research report on Monday, September 21st. Cantor Fitzgerald reiterated a "neutral" rating on shares of Alnylam Pharmaceuticals in a research note on Wednesday, September 30th. Jefferies Financial Group boosted their price target on Alnylam Pharmaceuticals from $230.00 to $260.00 and gave the company a "hold" rating in a research note on Tuesday, September 8th. Finally, Royal Bank Of Canada cut their price objective on Alnylam Pharmaceuticals from $445.00 to $350.00 and set an "outperform" rating on the stock in a report on Friday, July 31st. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $366.90.
Read Our Latest Analysis on ALNY
Institutional Trading of Alnylam Pharmaceuticals
Hedge funds and other institutional investors have recently made changes to their positions in the business. Bank of Nova Scotia grew its stake in Alnylam Pharmaceuticals by 0.6% in the 1st quarter. Bank of Nova Scotia now owns 7,798 shares of the biopharmaceutical company's stock worth $2,580,000 after acquiring an additional 49 shares during the period. Prestige Wealth Management Group LLC lifted its stake in shares of Alnylam Pharmaceuticals by 30.6% during the 1st quarter. Prestige Wealth Management Group LLC now owns 226 shares of the biopharmaceutical company's stock worth $75,000 after purchasing an additional 53 shares during the period. Glenmede Trust Co. NA boosted its holdings in shares of Alnylam Pharmaceuticals by 8.3% during the first quarter. Glenmede Trust Co. NA now owns 731 shares of the biopharmaceutical company's stock worth $242,000 after purchasing an additional 56 shares during the last quarter. MV Capital Management Inc. purchased a new stake in shares of Alnylam Pharmaceuticals in the fourth quarter valued at $25,000. Finally, Parallel Advisors LLC grew its position in shares of Alnylam Pharmaceuticals by 7.9% in the first quarter. Parallel Advisors LLC now owns 891 shares of the biopharmaceutical company's stock valued at $295,000 after purchasing an additional 65 shares during the period. Institutional investors and hedge funds own 92.97% of the company's stock.
Alnylam Pharmaceuticals Company Profile
(
Get Free Report)
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines based on RNA interference (RNAi), a biological process that can selectively reduce the production of disease-causing proteins. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Alnylam's commercial products include ONPATTRO (patisiran), an RNAi therapy for hereditary transthyretin-mediated amyloidosis with polyneuropathy; GIVLAARI (givosiran), for acute hepatic porphyria; OXLUMO (lumasiran), for primary hyperoxaluria type 1; and AMVUTTRA (vutrisiran), for transthyretin-mediated amyloidosis.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
